

## Update on Funding Strategy

Universal Biosensors, Inc. (ASX: UBI) (**Company**) provides an update regarding its funding strategy and the non-binding term sheet announced on 2 July 2025 with its substantial securityholder, Viburnum Funds Pty Ltd (**Viburnum**) in respect of a proposed secured loan facility.

While discussions regarding the proposed secured loan facility remain ongoing, the Company and Viburnum are continuing to explore alternative funding structures and it is currently expected that the structure of the funding transaction as previously announced will be varied. One such alternative funding structure currently being considered includes a pro rata entitlement offer of new CDIs over new fully paid shares of common stock in the Company to all eligible existing securityholders of the Company (**Entitlement Offer**). The terms of any Entitlement Offer, including as to timing and pricing, remain subject to ongoing discussion and negotiation.

At this stage, no binding commitment has been made by Viburnum in relation to the proposed Entitlement Offer. However, Viburnum has indicated that, subject to certain conditions being satisfied (including the Company continuing to progress the divestment of its healthcare and HRL assets), it would be prepared to take up its full pro rata entitlement and partially underwrite any shortfall under the Entitlement Offer.

In light of these developments, the Company advises that the milestone dates in the indicative timetable for the proposed funding transaction as described in its announcement on 2 July 2025 will not be met as originally contemplated. To facilitate the ongoing discussions, Viburnum has agreed to extend the due diligence period under the non-binding term sheet previously announced by one week to Friday, 15 August 2025.

The Company will provide a further market update, including a revised indicative timetable, once the terms of the revised funding transaction has been finalised with Viburnum.

**End**

***Announcement authorised by the Board of Directors of Universal Biosensors, Inc.***

For further information contact:  
Graham McLean  
Chair  
+61 (0) 416 190 764

### **About Universal Biosensors**

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. UBI's ambition is to build a multi product stable of biosensors in large markets which generate ongoing revenue streams. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

### **About Petrackr Blood Glucose Monitoring System**

The PETRACKR® Veterinary Blood Glucose Monitoring System is specifically calibrated for cats and dogs. The starter kit and PETRACKR® App allows pet parents to easily track, monitor and share their pet's blood glucose results with their veterinarian. The analyzer is Bluetooth enabled to connect with the PETRACKR® mobile app to track, download and share the pet's blood glucose results, insulin doses, meals, and exercise routine. The PETRACKR® handheld Point of Care analyzer puts the power of a lab in the palm of your hand. For additional information visit:

<https://www.universalbiosensors.com/products/petrackr/>

### **Forward-Looking Statements**

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.